Company profile
Aligos Therapeutics, Inc.
NASDAQ:ALGSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Pevifoscorvir Sodium | phase2 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05840952 | phase1 | completed | 2023-07-04 | 2024-04-29 | Aligos Therapeutics | A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 |
| NCT06672900 | phase1 | active_not_recruiting | 2025-01-09 | 2025-07-07 | Aligos Therapeutics | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers |
| NCT06959888 | phase1 | completed | 2025-03-25 | 2025-05-08 | Aligos Therapeutics | A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations |
| NCT06191991 | phase1 | completed | 2023-11-03 | 2023-11-27 | Aligos Therapeutics | A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) |
| NCT06963710 | phase2 | active_not_recruiting | 2025-07-15 | 2027-03-01 | Aligos Therapeutics | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) |
FDA applications (0)
No records yet.